본문 바로가기
KERD
논문KCI 등재

2016년 대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안

2016 Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer

정재훈|박소연|김선욱|이은경|박진우|정기욱|나동규|이병주|정유석|천기정|김원배|남기현|강호철|김인주|백승국|노영수|배상균|백정환|고윤우|이가희
대한갑상선학회 (Korean Thyroid Association)|2016.11|International Journal of Thyroidology|제9권 제2호|pp. 59-126

2

조회

0

다운로드

56

인용

0

참고문헌

주제분류의학일반

참고문헌 (602)

  1. 김원배, "갑상선결절 및 암 진료 권고안", Endocrinology and Metabolism, 22(3), pp.157~187 (2007), 대한내분비학회
  2. Yi KH, "Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer", J Korean Thyroid Assoc, 3(2), pp.65~96 (2010)
  3. Ito Y, "Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation", Thyroid, 24(1), pp.27~34 (2014)
  4. Sugitani I, "Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes", World J Surg, 34(6), pp.1222~1231 (2010)
  5. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136(5), pp.E359~E386 (2015)
  6. Haugen BR, "2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
  7. 이가희, "갑상선암 검진 권고안", 대한의사협회지, 58(4), pp.302~312 (2015), 대한의사협회[DOI]
  8. Gharib H, "American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update", Endocr Pract, 22(5), pp.622~639 (2016)
  9. Marqusee E, "Usefulness of ultrasonography in the management of nodular thyroid disease", Ann Intern Med, 133(9), pp.696~700 (2000)
  10. Hagag P, "Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules", Thyroid, 8(11), pp.989~995 (1998)
  11. Capezzone M, "Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity", Endocr Relat Cancer, 15(4), pp.1075~1081 (2008)
  12. Park YJ, "The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases", Thyroid, 22(4), pp.356~362 (2012)
  13. Mazeh H, "In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease", Thyroid, 22(1), pp.3~8 (2012)
  14. Robenshtok E, "Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study", Thyroid, 21(1), pp.43~48 (2011)
  15. Richards ML, "Familial syndromes associated with thyroid cancer in the era of personalized medicine", Thyroid, 20(7), pp.707~713 (2010)
  16. Curtis RE, "Solid cancers after bone marrow transplantation", N Engl J Med, 336(13), pp.897~904 (1997)
  17. Pacini F, "Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France", J Clin Endocrinol Metab, 82(11), pp.3563~3569 (1997)
  18. Gharib H, "Thyroid nodules: clinical importance, assessment, and treatment", Endocrinol Metab Clin North Am, 36(3), pp.707~735 (2007)
  19. Hall TL, "Sources of diagnostic error in fine needle aspiration of the thyroid", Cancer, 63(4), pp.718~725 (1989)
  20. Brander A, "Clinical versus ultrasound examination of the thyroid gland in common clinical practice", J Clin Ultrasound, 20(1), pp.37~42 (1992)
  21. Tan GH, "Solitary thyroid nodule. Comparison between palpation and ultrasonography", Arch Intern Med, 155(22), pp.2418~2423 (1995)
  22. Singh B, "Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome", Surgery, 126(6), pp.1070~1076 (1999)
  23. Repplinger D, "Hashimoto's thyroiditis a risk factor for papillary thyroid cancer", J Surg Res, 150(1), pp.49~52 (2008)
  24. Boelaert K, "Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration", J Clin Endocrinol Metab, 91(11), pp.4295~4301 (2006)
  25. Haymart MR, "Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage", J Clin Endocrinol Metab, 93(3), pp.809~814 (2008)
  26. Pacini F, "Serum thyroglobulin in thyroid carcinoma and other thyroid disorders", J Endocrinol Invest, 3(3), pp.283~292 (1980)
  27. Suh I, "Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid", Am J Surg, 200(1), pp.41~46 (2010)
  28. 이은경, "Preoperative Serum Thyroglobulin as a Useful Predictive Marker to Differentiate Follicular Thyroid Cancer from Benign Nodules in Indeterminate Nodules", Journal of Korean Medical Science, 27(9), pp.1014~1018 (2012), 대한의학회
  29. Elisei R, "Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders", J Clin Endocrinol Metab, 89(1), pp.163~168 (2004)
  30. Hahm JR, "Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases", Thyroid, 11(1), pp.73~80 (2001)
  31. Niccoli P, "Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group", J Clin Endocrinol Metab, 82(2), pp.338~341 (1997)
  32. Costante G, "Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules", J Clin Endocrinol Metab, 92(2), pp.450~455 (2007)
  33. Chambon G, "The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients", J Clin Endocrinol Metab, 96(1), pp.75~81 (2011)
  34. Colombo C, "Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer", J Clin Endocrinol Metab, 97(3), pp.905~913 (2012)
  35. Karga H, "Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin", Metabolism, 60(5), pp.604~608 (2011)
  36. Cheung K, "Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis", J Clin Endocrinol Metab, 93(6), pp.2173~2180 (2008)
  37. Gagel RF, "Werner & Ingbar's the thyroid: a fundamental and clinical text", pp.967~989 (2005), Lippincott Williams & Wilkins
  38. Chen W, "Evaluation of thyroid FDG uptake incidentally identified on FDG-PET", CT imaging, 2009, pp.30(3), 240~244
  39. Nishimori H, "Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake", Can J Surg, 54(2), pp.83~88 (2011)
  40. Soelberg KK, "Risk of malignancy in thyroid incidentalomas detected by 18Ffluorodeoxyglucose positron emission tomography: a systematic review", Thyroid, 22(9), pp.918~925 (2012)
  41. Frates MC, "Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement", Radiology, 237(3), pp.794~800 (2005)
  42. Papini E, "Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features", J Clin Endocrinol Metab, 87(5), pp.1941~1946 (2002)
  43. Moon WJ, "Benign and malignant thyroid nodules: US differentiation-- multicenter retrospective study", Radiology, 247(3), pp.762~770 (2008)
  44. Brito JP, "The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis", J Clin Endocrinol Metab, 99(4), pp.1253~1263 (2014)
  45. Remonti LR, "Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies", Thyroid, 25(5), pp.538~550 (2015)
  46. Campanella P, "Quantification of cancer risk of each clinical and ultrasonographic suspicious feature of thyroid nodules: a systematic review and meta-analysis", Eur J Endocrinol, 170(5), pp.R203~R211 (2014)
  47. Na DG, "Thyroid imaging reporting and data system risk stratification of thyroid nodules: categorization based on solidity and echogenicity", Thyroid, 26(4), pp.562~572 (2016)
  48. 신정희, "Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations", Korean Journal of Radiology, 17(3), pp.370~395 (2016), 대한영상의학회[DOI]
  49. Baloch ZW, "Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference", Diagn Cytopathol, 36(6), pp.425~437 (2008)
  50. Crippa S, "The Bethesda System for reporting thyroid fine-needle aspiration specimens", Am J Clin Pathol, 134(2), pp.343~344 (2010)
  51. Ali SZ, "The Bethesda system for reporting thyroid cytopathology. Definitions, criteria and explanatory notes", pp.1~166 (2010), Springer
  52. Bongiovanni M, "The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis", Acta Cytol, 56(4), pp.333~339 (2012)
  53. Theoharis CG, "The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution", Thyroid, 19(11), pp.1215~1223 (2009)
  54. Luu MH, "Improved preoperative definitive diagnosis of papillary thyroid carcinoma in FNAs prepared with both ThinPrep and conventional smears compared with FNAs prepared with ThinPrep alone", Cancer Cytopathol, 119(1), pp.68~73 (2011)
  55. Nayar R, "The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference", Cancer, 117(3), pp.195~202 (2009)
  56. Ohori NP, "Variability in the atypia of undetermined significance", follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: sources and recommendations, 2011, pp.55(6), 492~498
  57. Cibas ES, "A prospective assessment defining the limitations of thyroid nodule pathologic evaluation", Ann Intern Med, 159(5), pp.325~332 (2013)
  58. Nishino M, "Should the thyroid AUS", FLUS category be further stratified by malignancy risk, 2014, pp.122(7), 481~483
  59. Park HJ, "Thyroid "atypia of undetermined significance" with nuclear atypia has high rates of malignancy and BRAF mutation", Cancer Cytopathol, 122(7), pp.512~520 (2014)
  60. Baloch ZW, "Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations", Diagn Cytopathol, 23(6), pp.425~429 (2000)
  61. Braga M, "Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules", J Clin Endocrinol Metab, 86(9), pp.4089~4091 (2001)
  62. Redman R, "The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules", Thyroid, 16(1), pp.55~60 (2006)
  63. Orija IB, "Value of repeating a nondiagnostic thyroid fine-needle aspiration biopsy", Endocr Pract, 13(7), pp.735~742 (2007)
  64. Wu HH, "The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy", Diagn Cytopathol, 40(5), pp.399~403 (2012)
  65. Layfield LJ, "Post-thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference", Diagn Cytopathol, 36(6), pp.442~448 (2008)
  66. Singh RS, "Timing of repeat thyroid fine-needle aspiration in the management of thyroid nodules", Acta Cytol, 55(6), pp.544~548 (2011)
  67. Lubitz CC, "Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy", Thyroid, 22(6), pp.590~594 (2012)
  68. Alexander EK, "Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules", J Clin Endocrinol Metab, 87(11), pp.4924~4927 (2002)
  69. Choi YS, "Clinical and ultrasonographic findings affecting nondiagnostic results upon the second fine needle aspiration for thyroid nodules", Ann Surg Oncol, 19(7), pp.2304~2309 (2012)
  70. Moon HJ, "How to manage thyroid nodules with two consecutive non-diagnostic results on ultrasonography-guided fine-needle aspiration", World J Surg, 36(3), pp.586~592 (2012)
  71. Na DG, "Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology", Thyroid, 22(5), pp.468~475 (2012)
  72. Nam SY, "BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular", Thyroid, 20(3), pp.273~279 (2010)
  73. Yip L, "Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation", Surgery, 149(6), pp.1215~1223 (2009)
  74. Cantara S, "Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology", J Clin Endocrinol Metab, 95(3), pp.1365~1369 (2010)
  75. Chehade JM, "Role of repeated fine-needle aspiration of thyroid nodules with benign cytologic features", Endocr Pract, 7(4), pp.237~243 (2001)
  76. Orlandi A, "Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up", Thyroid, 15(3), pp.274~278 (2005)
  77. Oertel YC, "Value of repeated fine needle aspirations of the thyroid: an analysis of over ten thousand FNAs", Thyroid, 17(11), pp.1061~1066 (2007)
  78. Erdogan MF, "Value of re-aspirations in benign nodular thyroid disease", Thyroid, 8(12), pp.1087~1090 (1998)
  79. Illouz F, "Usefulness of repeated fine-needle cytology in the follow-up of non-operated thyroid nodules", Eur J Endocrinol, 156(3), pp.303~308 (2007)
  80. Tee YY, "Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review", Ann Surg, 246(5), pp.714~720 (2007)
  81. Pinchot SN, "Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger", Arch Surg, 144(7), pp.649~655 (2009)
  82. Kuru B, "The false-negative rate of fine-needle aspiration cytology for diagnosing thyroid carcinoma in thyroid nodules", Langenbecks Arch Surg, 395(2), pp.127~132 (2010)
  83. Wharry LI, "Thyroid nodules (＞", =4 cm): can ultrasound and cytology reliably exclude cancer, 2014, pp.38(3), 614~621
  84. Yoon JH, "The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy and the sonographic differences between benign and malignant thyroid nodules 3 cm or larger", Thyroid, 21(9), pp.993~1000 (2011)
  85. Porterfield JR Jr, "Reliability of benign fine needle aspiration cytology of large thyroid nodules", Surgery, 144(6), pp.963~968 (2008)
  86. Nou E, "Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration", J Clin Endocrinol Metab, 99(2), pp.510~516 (2014)
  87. Bongiovanni M, "Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multiinstitutional study", Cancer Cytopathol, 120(2), pp.117~125 (2012)
  88. Davidov T, "Routine second-opinion cytopathology review of thyroid fine needle aspiration biopsies reduces diagnostic thyroidectomy", Surgery, 148(6), pp.1294~1299 (2010)
  89. Kim SK, "Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status", J Clin Endocrinol Metab, 96(3), pp.658~664 (2011)
  90. Adeniran AJ, "BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance", Acta Cytol, 55(6), pp.570~575 (2011)
  91. Nikiforov YE, "Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples", J Clin Endocrinol Metab, 96(11), pp.3390~3397 (2011)
  92. Nikiforov YE, "Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules", J Clin Endocrinol Metab, 94(6), pp.2092~2098 (2009)
  93. Alexander EK, "Preoperative diagnosis of benign thyroid nodules with indeterminate cytology", N Engl J Med, 367(8), pp.705~715 (2012)
  94. Jeong SH, "Outcome of thyroid nodules characterized as atypia of undetermined significance or follicular lesion of undetermined significance and correlation with Ultrasound features and BRAF(V600E) mutation analysis", AJR Am J Roentgenol, 201(6), pp.W854~W860 (2013)
  95. Yoo WS, "The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance", Clin Endocrinol (Oxf), 80(5), pp.735~742 (2014)
  96. Gweon HM, "Thyroid nodules with Bethesda system III cytology: can ultrasonography guide the next step", Ann Surg Oncol, 20(9), pp.3083~3088 (2013)
  97. Kim DW, "Role of sonographic diagnosis in managing Bethesda class III nodules", AJNR Am J Neuroradiol, 32(11), pp.2136~2141 (2011)
  98. Nikiforov YE, "Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm", suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay, 2014, pp.120(23), 3627~3634
  99. Wang HH, "The Bethesda system for reporting thyroid cytopathology", pp.75~89 (2010), Springer
  100. Jara SM, "Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma"", Head Neck, 37(12), pp.1788~1793 (2015)
  101. Liu S, "Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population", Exp Mol Pathol, 97(2), pp.292~297 (2014)
  102. Hay ID, "Management of patients with low-risk papillary thyroid carcinoma", Endocr Pract, 13(5), pp.521~533 (2007)
  103. Mazzaferri EL, "Management of low-risk differentiated thyroid cancer", Endocr Pract, 13(5), pp.498~512 (2007)
  104. Bernet V, "AACE", ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology, 2014, pp.20(4), 360~363
  105. Ferris RL, "American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making", Thyroid, 25(7), pp.760~768 (2015)
  106. Wang N, "Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A metaanalysis of the literature", J Otolaryngol Head Neck Surg, 42, pp.38~ (2013)
  107. Vriens D, "Cost-effectiveness of FDG-PET", CT for cytologically indeterminate thyroid nodules: a decision analytic approach, 2014, pp.99(9), 3263~3274
  108. Deandreis D, "Is (18)F-fluorodeoxyglucose-PET", CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology, 2012, pp.22(2), 165~172
  109. Leenhardt L, "Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules", J Clin Endocrinol Metab, 84(1), pp.24~28 (1999)
  110. Carmeci C, "Ultrasound-guided fine-needle aspiration biopsy of thyroid masses", Thyroid, 8(4), pp.283~289 (1998)
  111. Ylagan LR, "Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases", Thyroid, 14(1), pp.35~41 (2004)
  112. Alexander EK, "Natural history of benign solid and cystic thyroid nodules", Ann Intern Med, 138(4), pp.315~318 (2003)
  113. Danese D, "Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules", Thyroid, 8(1), pp.15~21 (1998)
  114. Papini E, "Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules", J Clin Endocrinol Metab, 83(3), pp.780~783 (1998)
  115. Brander AE, "Importance of thyroid abnormalities detected at US screening: a 5-year follow-up", Radiology, 215(3), pp.801~806 (2000)
  116. Durante C, "The natural history of benign thyroid nodules", JAMA, 313(9), pp.926~935 (2015)
  117. Zelmanovitz F, "Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses", J Clin Endocrinol Metab, 83(11), pp.3881~3885 (1998)
  118. Wemeau JL, "Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group", J Clin Endocrinol Metab, 87(11), pp.4928~4934 (2002)
  119. Castro MR, "Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis", J Clin Endocrinol Metab, 87(9), pp.4154~4159 (2002)
  120. Ahn JE, "Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer", World J Surg, 32(7), pp.1552~1558 (2008)
  121. Kim E, "Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography", Thyroid, 18(4), pp.411~418 (2008)
  122. Lee DW, "Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma", Eur J Surg Oncol, 39(2), pp.191~196 (2013)
  123. Lesnik D, "Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients", Head Neck, 36(2), pp.191~202 (2014)
  124. Yeh MW, "American Thyroid Association statement on preoperative imaging for thyroid cancer surgery", Thyroid, 25(1), pp.3~14 (2015)
  125. Solorzano CC, "Surgeon-performed ultrasound in the management of thyroid malignancy", Am Surg, 70(7), pp.576~580 (2004)
  126. Shimamoto K, "Preoperative staging of thyroid papillary carcinoma with ultrasonography", Eur J Radiol, 29(1), pp.4~10 (1998)
  127. Sivanandan R, "Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid", Br J Surg, 88(9), pp.1241~1244 (2001)
  128. Ha EJ, "Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network metaanalysis", J Clin Endocrinol Metab, 100(5), pp.1903~1911 (2015)
  129. 백정환, "Radiofrequency versus Ethanol Ablation for Treating Predominantly Cystic Thyroid Nodules: A Randomized Clinical Trial", Korean Journal of Radiology, 16(6), pp.1332~1340 (2015), 대한영상의학회[DOI]
  130. Sung JY, "Single-session treatment of benign cystic thyroid nodules with ethanol versus radiofrequency ablation: a prospective randomized study", Radiology, 269(1), pp.293~300 (2013)
  131. 나동규, "Radiofrequency Ablation of Benign Thyroid Nodules and Recurrent Thyroid Cancers: Consensus Statement and Recommendations", Korean Journal of Radiology, 13(2), pp.117~125 (2012), 대한영상의학회
  132. Gharib H, "American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules", Endocr Pract, 16(Suppl 1), pp.1~43 (2010)
  133. Choi WJ, "Management of cystic or predominantly cystic thyroid nodules: role of simple aspiration of internal fluid", Endocr Res, 40(4), pp.215~219 (2015)
  134. Gharib H, "Clinical review: Nonsurgical, image-guided, minimally invasive therapy for thyroid nodules", J Clin Endocrinol Metab, 98(10), pp.3949~3957 (2013)
  135. Leenhardt L, "2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer", Eur Thyroid J, 2(3), pp.147~159 (2013)
  136. Camargo R, "Latin American thyroid society recommendations for the management of thyroid nodules", Arq Bras Endocrinol Metabol, 53(9), pp.1167~1175 (2009)
  137. Sung JY, "Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study", Thyroid, 25(1), pp.112~117 (2015)
  138. Tan GH, "Management of thyroid nodules in pregnancy", Arch Intern Med, 156(20), pp.2317~2320 (1996)
  139. Kung AW, "The effect of pregnancy on thyroid nodule formation", J Clin Endocrinol Metab, 87(3), pp.1010~1014 (2002)
  140. Mestman JH, "Thyroid disorders of pregnancy", Endocrinol Metab Clin North Am, 24(1), pp.41~71 (1995)
  141. Herzon FS, "Coexistent thyroid cancer and pregnancy", Arch Otolaryngol Head Neck Surg, 120(11), pp.1191~1193 (1994)
  142. Moosa M, "Outcome of differentiated thyroid cancer diagnosed in pregnant women", J Clin Endocrinol Metab, 82(9), pp.2862~2866 (1997)
  143. Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer", Am J Med, 97(5), pp.418~428 (1994)
  144. Rosen IB, "Thyroid nodular disease in pregnancy: current diagnosis and management", Clin Obstet Gynecol, 40(1), pp.81~89 (1997)
  145. Aschebrook-Kilfoy B, "Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006", Thyroid, 21(2), pp.125~134 (2011)
  146. "Cancer", 1998, 2638~2648
  147. Hay ID, "Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989", Surgery, 114(6), pp.1050~1057 (1993)
  148. Shah MD, "Clinical course of thyroid carcinoma after neck dissection", Laryngoscope, 113(12), pp.2102~2107 (2003)
  149. Wang TS, "Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes", Arch Otolaryngol Head Neck Surg, 130(1), pp.110~113 (2004)
  150. Mazzaferri EL, "An overview of the management of papillary and follicular thyroid carcinoma", Thyroid, 9(5), pp.421~427 (1999)
  151. Mazzaferri EL, "Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy", Endocr Pract, 6(6), pp.469~476 (2000)
  152. Cooper DS, "Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry", Thyroid, 8(9), pp.737~744 (1998)
  153. Lin JD, "Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation", Am J Clin Oncol, 21(1), pp.77~81 (1998)
  154. Brierley JD, "A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example", Cancer, 79(12), pp.2414~2423 (1997)
  155. Hay ID, "Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients", World J Surg, 26(8), pp.879~885 (2002)
  156. Sosa JA, "The importance of surgeon experience for clinical and economic outcomes from thyroidectomy", Ann Surg, 228(3), pp.320~330 (1998)
  157. Loyo M, "National trends in thyroid surgery and the effect of volume on short-term outcomes", Laryngoscope, 123(8), pp.2056~2063 (2013)
  158. Stavrakis AI, "Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery", Surgery, 142(6), pp.887~899 (2007)
  159. Qubain SW, "Distribution of lymph node micrometastasis in pN0 welldifferentiated thyroid carcinoma", Surgery, 131(3), pp.249~256 (2002)
  160. Arturi F, "Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes", J Clin Endocrinol Metab, 82(5), pp.1638~1641 (1997)
  161. Randolph GW, "The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension", Thyroid, 22(11), pp.1144~1152 (2012)
  162. Stulak JM, "Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer", Arch Surg, 141(5), pp.489~494 (2006)
  163. Kouvaraki MA, "Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer", Surgery, 134(6), pp.946~954 (2003)
  164. O'Connell K, "The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer", Surgery, 154(4), pp.697~701 (2013)
  165. Leboulleux S, "Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer", J Clin Endocrinol Metab, 92(9), pp.3590~3594 (2007)
  166. Grani G, "Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy", J Clin Endocrinol Metab, 99(6), pp.1970~1982 (2014)
  167. Pak K, "Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer", Endocrine, 49(1), pp.70~77 (2015)
  168. Duren M, "Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region", World J Surg, 24(11), pp.1290~1294 (2000)
  169. Stojadinovic A, "Development of a clinical decision model for thyroid nodules", BMC Surg, 9, pp.12~ (2009)
  170. Tuttle RM, "Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration", Thyroid, 8(5), pp.377~383 (1998)
  171. Goldstein RE, "Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules", Ann Surg, 235(5), pp.656~662 (2002)
  172. Schlinkert RT, "Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm"", Mayo Clin Proc, 72(10), pp.913~916 (1997)
  173. Mehta RS, "Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology", Surgery, 154(4), pp.730~736 (2013)
  174. Kandil E, "Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications", ORL J Otorhinolaryngol Relat Spec, 75(1), pp.6~17 (2013)
  175. Verloop H, "Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies", J Clin Endocrinol Metab, 97(7), pp.2243~2255 (2012)
  176. Gourin CG, "Volume-based trends in thyroid surgery", Arch Otolaryngol Head Neck Surg, 136(12), pp.1191~1198 (2010)
  177. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
  178. Bilimoria KY, "Extent of surgery affects survival for papillary thyroid cancer", Ann Surg, 246(3), pp.375~381 (2007)
  179. Grant CS, "Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important", Surgery, 104(6), pp.954~962 (1988)
  180. Hay ID, "Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma", Surgery, 124(6), pp.958~964 (1998)
  181. Mazzaferri EL, "Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer", J Clin Endocrinol Metab, 86(4), pp.1447~1463 (2001)
  182. Matsuzu K, "Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases", World J Surg, 38(1), pp.68~79 (2014)
  183. Barney BM, "Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer", Head Neck, 33(5), pp.645~649 (2011)
  184. Mendelsohn AH, "Surgery for papillary thyroid carcinoma: is lobectomy enough", Arch Otolaryngol Head Neck Surg, 136(11), pp.1055~1061 (2010)
  185. Haigh PI, "Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer", Ann Surg Oncol, 12(1), pp.81~89 (2005)
  186. Nixon IJ, "Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy", Surgery, 151(4), pp.571~579 (2012)
  187. Adam MA, "Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients", Ann Surg, 260(4), pp.601~605 (2014)
  188. Vaisman F, "Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer", Clin Endocrinol (Oxf), 75(1), pp.112~119 (2011)
  189. Tuggle CT, "Same-day thyroidectomy: a review of practice patterns and outcomes for 1,168 procedures in New York State", Ann Surg Oncol, 18(4), pp.1035~1040 (2011)
  190. Tuggle CT, "Pediatric endocrine surgery: who is operating on our children", Surgery, 144(6), pp.869~877 (2008)
  191. Kandil E, "The impact of surgical volume on patient outcomes following thyroid surgery", Surgery, 154(6), pp.1346~1352 (2013)
  192. Hughes DT, "Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer", Surgery, 148(6), pp.1100~1106 (2010)
  193. Podnos YD, "The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer", Am Surg, 71(9), pp.731~734 (2005)
  194. Zaydfudim V, "The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma", Surgery, 144(6), pp.1070~1077 (2008)
  195. Leboulleux S, "Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and", or tumor extension beyond the thyroid capsule at initial diagnosis, 2005, pp.90(10), 5723~5729
  196. Sugitani I, "A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period", Surgery, 135(2), pp.139~148 (2004)
  197. Adam MA, "Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer", J Clin Oncol, 33(21), pp.2370~2375 (2015)
  198. Robbins KT, "Consensus statement on the classification and terminology of neck dissection", Arch Otolaryngol Head Neck Surg, 134(5), pp.536~538 (2008)
  199. Hwang HS, "Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer", Laryngoscope, 121(3), pp.487~491 (2011)
  200. Mulla M, "Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment", Clin Endocrinol (Oxf), 76(1), pp.131~136 (2012)
  201. Hartl DM, "Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma", Ann Surg, 255(4), pp.777~783 (2012)
  202. Popadich A, "A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer", Surgery, 150(6), pp.1048~1057 (2011)
  203. Lang BH, "Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma", Ann Surg Oncol, 19(1), pp.60~67 (2012)
  204. Wang TS, "Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer", Ann Surg Oncol, 19(13), pp.4217~4222 (2012)
  205. American Thyroid Association Surgery Working Group, "Consensus statement on the terminology and classification of central neck dissection for thyroid cancer", Thyroid, 19(11), pp.1153~1158 (2009)
  206. Chisholm EJ, "Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone", Laryngoscope, 119(6), pp.1135~1139 (2009)
  207. Bonnet S, "Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment", J Clin Endocrinol Metab, 94(4), pp.1162~1167 (2009)
  208. Sancho JJ, "Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES)", Langenbecks Arch Surg, 399(2), pp.155~163 (2014)
  209. Zetoune T, "Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis", Ann Surg Oncol, 17(12), pp.3287~3293 (2010)
  210. Barczynski M, "Prophylactic central neck dissection for papillary thyroid cancer", Br J Surg, 100(3), pp.410~418 (2013)
  211. Hartl DM, "Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma", World J Surg, 37(8), pp.1951~1958 (2013)
  212. Sywak M, "Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer", Surgery, 140(6), pp.1000~1005 (2006)
  213. Laird AM, "Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection", World J Surg, 36(6), pp.1268~1273 (2012)
  214. Moreno MA, "In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival", Thyroid, 22(4), pp.347~355 (2012)
  215. Yoo D, "Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer", World J Surg, 36(6), pp.1255~1261 (2012)
  216. Roh JL, "Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone", Ann Surg, 245(4), pp.604~610 (2007)
  217. Cavicchi O, "Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients", Otolaryngol Head Neck Surg, 137(4), pp.654~658 (2007)
  218. Raffaelli M, "Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma", Surgery, 152(6), pp.957~964 (2012)
  219. Viola D, "Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study", J Clin Endocrinol Metab, 100(4), pp.1316~1324 (2015)
  220. Lang BH, "A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy", Thyroid, 23(9), pp.1087~1098 (2013)
  221. Wang TS, "A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer", Ann Surg Oncol, 20(11), pp.3477~3483 (2013)
  222. Gyorki DE, "Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence", Ann Surg Oncol, 20(7), pp.2285~2289 (2013)
  223. Howell GM, "BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer", Ann Surg Oncol, 20(1), pp.47~52 (2013)
  224. Xing M, "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer", JAMA, 309(14), pp.1493~1501 (2013)
  225. Kim TH, "The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis", Cancer, 118(7), pp.1764~1773 (2012)
  226. Ito Y, "BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients", World J Surg, 38(3), pp.679~687 (2014)
  227. Gouveia C, "Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience", JAMA Otolaryngol Head Neck Surg, 139(11), pp.1164~1170 (2013)
  228. Dutenhefner SE, "BRAF: a tool in the decision to perform elective neck dissection", Thyroid, 23(12), pp.1541~1546 (2013)
  229. Lee KC, "Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer", Surgery, 152(6), pp.977~983 (2012)
  230. Xing M, "Prognostic utility of BRAF mutation in papillary thyroid cancer", Mol Cell Endocrinol, 321(1), pp.86~93 (2010)
  231. Scheumann GF, "Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer", World J Surg, 18(4), pp.559~567 (1994)
  232. Sugitani I, "Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography", World J Surg, 32(11), pp.2494~2502 (2008)
  233. Ito Y, "Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks", World J Surg, 31(5), pp.905~915 (2007)
  234. Gemsenjager E, "Lymph node surgery in papillary thyroid carcinoma", J Am Coll Surg, 197(2), pp.182~190 (2003)
  235. Kouvaraki MA, "Preventable reoperations for persistent and recurrent papillary thyroid carcinoma", Surgery, 136(6), pp.1183~1191 (2004)
  236. Ito Y, "Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid", World J Surg, 28(5), pp.498~501 (2004)
  237. Erdem E, "Comparison of completion thyroidectomy and primary surgery for differentiated thyroid carcinoma", Eur J Surg Oncol, 29(9), pp.747~749 (2003)
  238. Tan MP, "Impact of timing on completion thyroidectomy for thyroid cancer", Br J Surg, 89(6), pp.802~804 (2002)
  239. Untch BR, "Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma", Ann Surg Oncol, 21(4), pp.1374~1378 (2014)
  240. Husson O, "Health-related quality of life among thyroid cancer survivors: a systematic review", Clin Endocrinol (Oxf), 75(4), pp.544~554 (2011)
  241. Chandrasekhar SS, "Clinical practice guideline: improving voice outcomes after thyroid surgery", Otolaryngol Head Neck Surg, 148(6 Suppl), pp.S1~S37 (2013)
  242. Rowe-Jones JM, "Benign thyroid disease and vocal cord palsy", Ann R Coll Surg Engl, 75(4), pp.241~244 (1993)
  243. Bergenfelz A, "Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients", Langenbecks Arch Surg, 393(5), pp.667~673 (2008)
  244. Roh JL, "Recurrent laryngeal nerve paralysis in patients with papillary thyroid carcinomas: evaluation and management of resulting vocal dysfunction", Am J Surg, 197(4), pp.459~465 (2009)
  245. Eadie TL, "The role of experience on judgments of dysphonia", J Voice, 24(5), pp.564~573 (2010)
  246. Jatzko GR, "Recurrent nerve palsy after thyroid operations--principal nerve identification and a literature review", Surgery, 115(2), pp.139~144 (1994)
  247. Randolph GW, "Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement", Laryngoscope, 121(Suppl 1), pp.S1~S16 (2011)
  248. Pisanu A, "Systematic review with meta-analysis of studies comparing intraoperative neuromonitoring of recurrent laryngeal nerves versus visualization alone during thyroidectomy", J Surg Res, 188(1), pp.152~161 (2014)
  249. Goretzki PE, "The impact of intraoperative neuromonitoring (IONM) on surgical strategy in bilateral thyroid diseases: is it worth the effort", World J Surg, 34(6), pp.1274~1284 (2010)
  250. Barczynski M, "Intraoperative nerve monitoring can reduce prevalence of recurrent laryngeal nerve injury in thyroid reoperations: results of a retrospective cohort study", World J Surg, 38(3), pp.599~606 (2014)
  251. Barczynski M, "Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy", Br J Surg, 96(3), pp.240~246 (2009)
  252. Barczynski M, "Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy", World J Surg, 36(6), pp.1340~1347 (2012)
  253. Friedman AD, "Early versus late injection medialization for unilateral vocal cord paralysis", Laryngoscope, 120(10), pp.2042~2046 (2010)
  254. Loh KC, "Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients", J Clin Endocrinol Metab, 82(11), pp.3553~3562 (1997)
  255. DeGroot LJ, "Natural history, treatment, and course of papillary thyroid carcinoma", J Clin Endocrinol Metab, 71(2), pp.414~424 (1990)
  256. Byar DP, "A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group", Eur J Cancer, 15(8), pp.1033~1041 (1979)
  257. Shaha AR, "Prognostic factors and risk group analysis in follicular carcinoma of the thyroid", Surgery, 118(6), pp.1131~1136 (1995)
  258. Sherman SI, "Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group", Cancer, 83(5), pp.1012~1021 (1998)
  259. Cady B, "An expanded view of risk-group definition in differentiated thyroid carcinoma", Surgery, 104(6), pp.947~953 (1988)
  260. Tuttle RM, "Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system", Thyroid, 20(12), pp.1341~1349 (2010)
  261. Tuttle RM, "Follow up approaches in thyroid cancer: a risk adapted paradigm", Endocrinol Metab Clin North Am, 37(2), pp.419~435 (2008)
  262. Momesso DP, "Update on differentiated thyroid cancer staging", Endocrinol Metab Clin North Am, 43(2), pp.401~421 (2014)
  263. Vaisman F, "Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy", Clin Endocrinol (Oxf), 77(1), pp.132~138 (2012)
  264. Castagna MG, "Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients", Eur J Endocrinol, 165(3), pp.441~446 (2011)
  265. Berger F, "Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up", Eur J Nucl Med Mol Imaging, 38(3), pp.451~458 (2011)
  266. Malandrino P, "Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin", J Clin Endocrinol Metab, 96(6), pp.1703~1709 (2011)
  267. Soyluk O, "Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment", Thyroid, 21(12), pp.1301~1308 (2011)
  268. Piccardo A, "Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer", J Endocrinol Invest, 33(2), pp.83~87 (2010)
  269. Castagna MG, "Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels", J Clin Endocrinol Metab, 93(1), pp.76~81 (2008)
  270. Kloos RT, "A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later", J Clin Endocrinol Metab, 90(9), pp.5047~5057 (2005)
  271. Kloos RT, "Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values", J Clin Endocrinol Metab, 95(12), pp.5241~5248 (2010)
  272. Han JM, "Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment", Thyroid, 22(8), pp.784~790 (2012)
  273. Rosario PW, "Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation", Thyroid, 22(5), pp.482~486 (2012)
  274. Brassard M, "Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients", J Clin Endocrinol Metab, 96(5), pp.1352~1359 (2011)
  275. Pelttari H, "Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study", Eur J Endocrinol, 163(5), pp.757~763 (2010)
  276. Klubo-Gwiezdzinska J, "Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission", Clin Endocrinol (Oxf), 74(1), pp.111~117 (2011)
  277. Crocetti U, "Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients", Thyroid, 18(10), pp.1049~1053 (2008)
  278. Torlontano M, "Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases", J Clin Endocrinol Metab, 89(7), pp.3402~3407 (2004)
  279. Verburg FA, "No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 37(2), pp.276~283 (2010)
  280. Giovanella L, "Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma", Clin Chem Lab Med, 47(8), pp.1001~1004 (2009)
  281. Lemb J, "How reliable is secondary risk stratification with stimulated thyroglobulin in patients with differentiated thyroid carcinoma? Results from a retrospective study", Nuklearmedizin, 52(3), pp.88~96 (2013)
  282. Vaisman F, "In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response", Thyroid, 21(12), pp.1317~1322 (2011)
  283. Verburg FA, "Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement", Thyroid, 23(10), pp.1211~1225 (2013)
  284. Spencer CA, "Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 83(4), pp.1121~1127 (1998)
  285. Chung JK, "Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation", Clin Endocrinol (Oxf), 57(2), pp.215~221 (2002)
  286. Gorges R, "Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy", Eur J Endocrinol, 153(1), pp.49~55 (2005)
  287. Seo JH, "Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET", CT, 2010, pp.72(4), 558~563
  288. Adil A, "Frequency and clinical importance of anti-Tg auto-antibodies (ATG)", J Coll Physicians Surg Pak, 13(9), pp.504~506 (2003)
  289. Kim WG, "Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulinnegative patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 93(12), pp.4683~4689 (2008)
  290. Chiovato L, "Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens", Ann Intern Med, 139(5 Pt 1), pp.346~351 (2003)
  291. Thomas D, "Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation", J Endocrinol Invest, 30(3), pp.173~180 (2007)
  292. Castagna MG, "The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma", J Endocrinol Invest, 34(8), pp.e219~e223 (2011)
  293. Baudin E, "Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients", J Clin Endocrinol Metab, 88(3), pp.1107~1111 (2003)
  294. Pineda JD, "Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan", J Clin Endocrinol Metab, 80(5), pp.1488~1492 (1995)
  295. Alzahrani AS, "Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer", J Endocrinol Invest, 28(6), pp.540~546 (2005)
  296. Valadao MM, "Positive predictive value of detectable stimulated tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months", Thyroid, 16(11), pp.1145~1149 (2006)
  297. Miyauchi A, "Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy", Thyroid, 21(7), pp.707~716 (2011)
  298. Wong H, "Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation", Ann Surg Oncol, 19(11), pp.3479~3485 (2012)
  299. Hsieh CJ, "Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma", Thyroid, 24(3), pp.488~493 (2014)
  300. Schuff KG, "Efficacy of nodal dissection for treatment of persistent", recurrent papillary thyroid cancer, 2008, pp.118(5), 768~775
  301. Al-Saif O, "Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer", J Clin Endocrinol Metab, 95(5), pp.2187~2194 (2010)
  302. Yim JH, "The outcomes of first reoperation for locoregionally recurrent", persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation, 2011, pp.96(7), 2049~2056
  303. Chindris AM, "Undetectable sensitive serum thyroglobulin (＜0.1 ng", ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up, 2012, pp.97(8), 2714~2723
  304. Rondeau G, "Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression", Thyroid, 21(8), pp.845~853 (2011)
  305. Webb RC, "The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients", J Clin Endocrinol Metab, 97(8), pp.2754~2763 (2012)
  306. Giovanella L, "Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 69(4), pp.659~663 (2008)
  307. Giovanella L, "Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma", Clin Chem Lab Med, 43(8), pp.843~847 (2005)
  308. Phan HT, "The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation", Eur J Endocrinol, 158(1), pp.77~83 (2008)
  309. Vaisman A, "Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma", Head Neck, 32(6), pp.689~698 (2010)
  310. Kim TY, "Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 90(3), pp.1440~1445 (2005)
  311. Toubeau M, "Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer", J Nucl Med, 45(6), pp.988~994 (2004)
  312. Piccardo A, "Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival", Clin Nucl Med, 38(1), pp.18~24 (2013)
  313. Polachek A, "Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer", J Endocrinol Invest, 34(11), pp.855~860 (2011)
  314. Heemstra KA, "Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 66(1), pp.58~64 (2007)
  315. Lin JD, "Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas", J Surg Oncol, 80(1), pp.45~51 (2002)
  316. Lee JI, "Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma", Surgery, 153(6), pp.828~835 (2013)
  317. Lepoutre-Lussey C, "Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement", Eur J Endocrinol, 170(6), pp.837~846 (2014)
  318. Avram AM, "Preablation 131-I scans with SPECT", CT in postoperative thyroid cancer patients: what is the impact on staging, 2013, pp.98(3), 1163~1171
  319. Chen MK, "The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer", Thyroid, 22(3), pp.304~309 (2012)
  320. Van Nostrand D, "The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer", Thyroid, 19(8), pp.849~855 (2009)
  321. Gerard SK, "I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours", Clin Nucl Med, 27(1), pp.1~8 (2002)
  322. Chakravarty D, "Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation", J Clin Invest, 121(12), pp.4700~4711 (2011)
  323. Schvartz C, "Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients", J Clin Endocrinol Metab, 97(5), pp.1526~1535 (2012)
  324. Jonklaas J, "Outcomes of patients with differentiated thyroid carcinoma following initial therapy", Thyroid, 16(12), pp.1229~1242 (2006)
  325. Jonklaas J, "Radioiodine therapy in patients with stage I differentiated thyroid cancer", Thyroid, 20(12), pp.1423~1424 (2010)
  326. Lamartina L, "Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature", J Clin Endocrinol Metab, 100(5), pp.1748~1761 (2015)
  327. Podnos YD, "Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope", J Surg Oncol, 96(1), pp.3~7 (2007)
  328. Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer", N Engl J Med, 366(18), pp.1674~1685 (2012)
  329. Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med, 366(18), pp.1663~1673 (2012)
  330. 하승균, "Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer", Journal of Korean Medical Science, 30(7), pp.876~881 (2015), 대한의학회
  331. Sohn SY, "Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer", Thyroid, 23(6), pp.741~747 (2013)
  332. Verburg FA, "Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 43(6), pp.1001~1005 (2016)
  333. Blumhardt R, "Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review", Endocr Relat Cancer, 21(6), pp.R473~R484 (2014)
  334. Edmonds CJ, "Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine", Br J Radiol, 50(599), pp.799~807 (1977)
  335. Torres MS, "Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects", J Clin Endocrinol Metab, 86(4), pp.1660~1664 (2001)
  336. Hershman JM, "Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma", J Clin Endocrinol Metab, 34(5), pp.814~818 (1972)
  337. Hilts SV, "Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma", J Nucl Med, 20(9), pp.928~932 (1979)
  338. Martin ND, "Endogenous serum TSH levels and metastatic survey scans in thyroid cancer patients using triiodothyronine withdrawal", Clin Nucl Med, 3(10), pp.401~403 (1978)
  339. Goldman JM, "Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer", J Clin Endocrinol Metab, 50(4), pp.734~739 (1980)
  340. Schneider AB, "Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer", J Clin Endocrinol Metab, 53(6), pp.1199~1206 (1981)
  341. Maxon HR, "Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer", N Engl J Med, 309(16), pp.937~941 (1983)
  342. Liel Y, "Preparation for radioactive iodine administration in differentiated thyroid cancer patients", Clin Endocrinol (Oxf), 57(4), pp.523~527 (2002)
  343. Sanchez R, "Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma", Arch Med Res, 33(5), pp.478~481 (2002)
  344. Grigsby PW, "Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation", J Nucl Med, 45(4), pp.567~570 (2004)
  345. Serhal DI, "Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer", J Clin Endocrinol Metab, 89(7), pp.3285~3289 (2004)
  346. Lee J, "Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma", Thyroid, 20(2), pp.173~179 (2010)
  347. Leboeuf R, "L-T3 preparation for whole-body scintigraphy: a randomized- controlled trial", Clin Endocrinol (Oxf), 67(6), pp.839~844 (2007)
  348. Fallahi B, "Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial", Nucl Med Commun, 33(3), pp.275~282 (2012)
  349. Prpic M, "Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)", Ann Nucl Med, 26(9), pp.744~751 (2012)
  350. Karam M, "Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates", Nucl Med Commun, 24(5), pp.489~495 (2003)
  351. Robbins RJ, "Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine", Thyroid, 16(11), pp.1121~1130 (2006)
  352. Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study", J Clin Endocrinol Metab, 91(3), pp.926~932 (2006)
  353. Maxon HR, "Low iodine diet in I-131 ablation of thyroid remnants", Clin Nucl Med, 8(3), pp.123~126 (1983)
  354. Goslings BM, "Proceedings: Effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata", J Endocrinol, 64(3), pp.30~ (1975)
  355. Pluijmen MJ, "Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 58(4), pp.428~435 (2003)
  356. Park JT 2nd, "Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine", Thyroid, 14(1), pp.57~63 (2004)
  357. Tomoda C, "Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy", Endocr J, 52(2), pp.237~240 (2005)
  358. Morris LF, "Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma", Thyroid, 11(8), pp.749~755 (2001)
  359. Fatourechi V, "Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer", Thyroid, 10(7), pp.573~577 (2000)
  360. Sherman SI, "Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma", J Clin Endocrinol Metab, 78(3), pp.629~634 (1994)
  361. Souza Rosario PW, "Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution", Clin Nucl Med, 29(12), pp.795~798 (2004)
  362. Ciappuccini R, "Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer", Eur J Endocrinol, 164(6), pp.961~969 (2011)
  363. Kohlfuerst S, "Posttherapeutic (131)I SPECTCT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen", Eur J Nucl Med Mol Imaging, 36(6), pp.886~893 (2009)
  364. Chen L, "Incremental value of 131I SPECT", CT in the management of patients with differentiated thyroid carcinoma, 2008, pp.49(12), 1952~1957
  365. Schmidt D, "Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT", CT at the first radioablation, 2010, pp.37(4), 699~705
  366. Maruoka Y, "Incremental diagnostic value of SPECT", CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma, 2012, pp.265(3), 902~909
  367. Grewal RK, "The effect of posttherapy 131I SPECT", CT on risk classification and management of patients with differentiated thyroid cancer, 2010, pp.51(9), 1361~1367
  368. Brabant G, "Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets", J Clin Endocrinol Metab, 93(4), pp.1167~1169 (2008)
  369. Diessl S, "Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 76(4), pp.586~592 (2012)
  370. McGriff NJ, "Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer", Ann Med, 34(7-8), pp.554~564 (2002)
  371. Pujol P, "Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer", J Clin Endocrinol Metab, 81(12), pp.4318~4323 (1996)
  372. Wang PW, "Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 84(12), pp.4549~4553 (1999)
  373. Toft AD, "Clinical practice. Subclinical hyperthyroidism", N Engl J Med, 345(7), pp.512~516 (2001)
  374. Ebina A, "Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?", Surgery, 156(6), pp.1579~1588 (2014)
  375. Ford D, "External beam radiotherapy in the management of differentiated thyroid cancer", Clin Oncol (R Coll Radiol), 15(6), pp.337~341 (2003)
  376. Terezakis SA, "Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience", Int J Radiat Oncol Biol Phys, 73(3), pp.795~7801 (2009)
  377. Links TP, "Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis", Endocr Relat Cancer, 12(2), pp.273~280 (2005)
  378. Kim S, "Predicting outcome and directing therapy for papillary thyroid carcinoma", Arch Surg, 139(4), pp.390~394 (2004)
  379. Eustatia-Rutten CF, "Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis", Clin Endocrinol (Oxf), 61(1), pp.61~74 (2004)
  380. Schlumberger M, "Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective", Eur J Endocrinol, 150(2), pp.105~112 (2004)
  381. Bachelot A, "Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment", Clin Endocrinol (Oxf), 62(3), pp.376~379 (2005)
  382. Brierley JD, "External-beam radiation therapy in the treatment of differentiated thyroid cancer", Semin Surg Oncol, 16(1), pp.42~49 (1999)
  383. Ronga G, "Lung metastases from differentiated thyroid carcinoma. A 40 years' experience", Q J Nucl Med Mol Imaging, 48(1), pp.12~19 (2004)
  384. Schlumberger M, "Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma", J Nucl Med, 37(4), pp.598~605 (1996)
  385. Ilgan S, "Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma", Eur J Nucl Med Mol Imaging, 31(6), pp.825~830 (2004)
  386. Bernier MO, "Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas", J Clin Endocrinol Metab, 86(4), pp.1568~1573 (2001)
  387. Zettinig G, "Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy", Clin Endocrinol (Oxf), 56(3), pp.377~382 (2002)
  388. Spencer CA, "Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement", Thyroid, 9(5), pp.435~441 (1999)
  389. Hollowell JG, "Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)", J Clin Endocrinol Metab, 87(2), pp.489~499 (2002)
  390. Spencer CA, "Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies", J Clin Endocrinol Metab, 89(8), pp.3702~3704 (2004)
  391. Bachelot A, "Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma", Thyroid, 12(8), pp.707~711 (2002)
  392. David A, "Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma", Thyroid, 15(3), pp.267~273 (2005)
  393. Schaap J, "Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 57(1), pp.117~124 (2002)
  394. Spencer CA, "Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)", J Clin Endocrinol Metab, 96(12), pp.3615~3627 (2011)
  395. Latrofa F, "Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin", J Clin Endocrinol Metab, 97(7), pp.2380~2387 (2012)
  396. Giovanella L, "Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan", Clin Nucl Med, 36(2), pp.109~112 (2011)
  397. Cherk MH, "Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with welldifferentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal", Clin Endocrinol (Oxf), 76(5), pp.734~740 (2012)
  398. Torlontano M, "Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I wholebody scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy", J Clin Endocrinol Metab, 91(1), pp.60~63 (2006)
  399. Pacini F, "Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients", J Clin Endocrinol Metab, 86(9), pp.4092~4097 (2001)
  400. Frasoldati A, "Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma", Cancer, 97(1), pp.90~96 (2003)
  401. Diaz-Soto G, "Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing", Exp Clin Endocrinol Diabetes, 119(6), pp.348~352 (2011)
  402. Nascimento C, "Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level", Endocr Relat Cancer, 18(2), pp.R29~R40 (2011)
  403. Mazzaferri EL, "A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma", J Clin Endocrinol Metab, 88(4), pp.1433~1441 (2003)
  404. Iervasi A, "Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer", Clin Endocrinol (Oxf), 67(3), pp.434~441 (2007)
  405. Padovani RP, "Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer", Thyroid, 22(8), pp.778~783 (2012)
  406. Haugen BR, "A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer", J Clin Endocrinol Metab, 84(11), pp.3877~3885 (1999)
  407. David A, "Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone", J Nucl Med, 42(10), pp.1470~1475 (2001)
  408. Mazzaferri EL, "Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation", J Clin Endocrinol Metab, 87(4), pp.1490~1498 (2002)
  409. Haugen BR, "Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin", Thyroid, 12(1), pp.37~43 (2002)
  410. Lima N, "Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer", J Endocrinol Invest, 25(2), pp.110~115 (2002)
  411. Wartofsky L, "Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin", Thyroid, 12(7), pp.583~590 (2002)
  412. Pacini F, "Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer", Thyroid, 21(7), pp.691~692 (2011)
  413. Spencer C, "Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer", Best Pract Res Clin Endocrinol Metab, 27(5), pp.701~712 (2013)
  414. Durante C, "Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement", J Clin Endocrinol Metab, 97(8), pp.2748~2753 (2012)
  415. Pacini F, "Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma", J Clin Endocrinol Metab, 88(8), pp.3668~3673 (2003)
  416. Shin JH, "Sonographic findings in the surgical bed after thyroidectomy: comparison of recurrent tumors and nonrecurrent lesions", J Ultrasound Med, 26(10), pp.1359~1366 (2007)
  417. Bardet S, "Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma", Eur J Endocrinol, 158(4), pp.551~560 (2008)
  418. Spencer C, "Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer", Thyroid, 20(6), pp.587~595 (2010)
  419. Pacini F, "Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer", J Clin Endocrinol Metab, 74(6), pp.1401~1404 (1992)
  420. Torres MR, "Thyroglobulin in the washout fluid of lymph-node biopsy: what is its role in the follow-up of differentiated thyroid carcinoma", Thyroid, 24(1), pp.7~18 (2014)
  421. Frasoldati A, "Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer", Thyroid, 9(2), pp.105~111 (1999)
  422. Snozek CL, "Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases", J Clin Endocrinol Metab, 92(11), pp.4278~4281 (2007)
  423. Boi F, "The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies", J Clin Endocrinol Metab, 91(4), pp.1364~1369 (2006)
  424. Baloch ZW, "Utility of Thyroglobulin measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma", Cytojournal, 5, pp.1~ (2008)
  425. Pacini F, "Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment", J Clin Endocrinol Metab, 87(4), pp.1499~1501 (2002)
  426. Torlontano M, "Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer", Eur J Endocrinol, 148(1), pp.19~24 (2003)
  427. Aide N, "Clinical relevance of single-photon emission computed tomography", computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer, 2009, pp.94(6), 2075~2084
  428. Schmidt D, "Impact of 131I SPECT", spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation, 2009, pp.50(1), 18~23
  429. Jeong SY, "Clinical applications of SPECT", CT after first I-131 ablation in patients with differentiated thyroid cancer, 2014, pp.81(3), 445~451
  430. Tharp K, "Impact of 131I-SPECT", CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma, 2004, pp.31(10), 1435~1442
  431. Leboulleux S, "The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers", Nat Clin Pract Endocrinol Metab, 3(2), pp.112~121 (2007)
  432. fluoro-2-deoxy-D-glucose-positron emission tomography scanning, "J Clin Endocrinol Metab", 2006, 498~505
  433. Deandreis D, "Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome", Endocr Relat Cancer, 18(1), pp.159~169 (2011)
  434. - Fluoro-2-deoxy-D-glucose positron emission tomography, "computed tomography imaging to localize residual differentiated thyroid cancer", J Clin Endocrinol Metab, 94(4), pp.1310~1316 (2009)
  435. Yoon DY, "CT, MR, US,18F-FDG PET", CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck, 2009, pp.19(3), 634~642
  436. Padovani RP, "One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy", Thyroid, 22(9), pp.926~930 (2012)
  437. Choi JS, "Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT", AJR Am J Roentgenol, 193(3), pp.871~878 (2009)
  438. Takashima S, "Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis", AJNR Am J Neuroradiol, 19(3), pp.509~513 (1998)
  439. Gross ND, "MRI detection of cervical metastasis from differentiated thyroid carcinoma", Laryngoscope, 111(11 Pt 1), pp.1905~1909 (2001)
  440. Toubert ME, "Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits", Thyroid, 9(6), pp.591~597 (1999)
  441. Wang JC, "Tracheal invasion by thyroid carcinoma: prediction using MR imaging", AJR Am J Roentgenol, 177(4), pp.929~936 (2001)
  442. Wang J, "Esophageal invasion by thyroid carcinomas: prediction using magnetic resonance imaging", J Comput Assist Tomogr, 27(1), pp.18~25 (2003)
  443. Lee DH, "Detection of metastatic cervical lymph nodes in recurrent papillary thyroid carcinoma: computed tomography versus positron emission tomography-computed tomography", J Comput Assist Tomogr, 33(5), pp.805~810 (2009)
  444. Rosario PW, "Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin", Thyroid, 24(3), pp.533~536 (2014)
  445. Leboulleux S, "Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels", Thyroid, 22(8), pp.832~838 (2012)
  446. Hovens GC, "Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer", J Clin Endocrinol Metab, 92(7), pp.2610~2615 (2007)
  447. Sugitani I, "Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial", J Clin Endocrinol Metab, 95(10), pp.4576~4583 (2010)
  448. Klein Hesselink EN, "Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study", J Clin Oncol, 31(32), pp.4046~4053 (2013)
  449. Biondi B, "Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer", Thyroid, 20(2), pp.135~146 (2010)
  450. Shargorodsky M, "Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma", Thyroid, 16(4), pp.381~386 (2006)
  451. Taillard V, "Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy", Clin Endocrinol (Oxf), 75(5), pp.709~714 (2011)
  452. Dupuy DE, "Radiofrequency ablation of regional recurrence from welldifferentiated thyroid malignancy", Surgery, 130(6), pp.971~977 (2001)
  453. Lewis BD, "Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma", AJR Am J Roentgenol, 178(3), pp.699~704 (2002)
  454. Eustatia-Rutten CF, "Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma", J Clin Endocrinol Metab, 88(7), pp.3184~3189 (2003)
  455. Tufano RP, "Management of recurrent", persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance, 2015, pp.25(1), 15~27
  456. Phelan E, "Neural monitored revision thyroid cancer surgery: surgical safety and thyroglobulin response", Otolaryngol Head Neck Surg, 149(1), pp.47~52 (2013)
  457. Urken ML, "Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative", Head Neck, 37(4), pp.605~614 (2015)
  458. Merdad M, "Predictors of level II and Vb neck disease in metastatic papillary thyroid cancer", Arch Otolaryngol Head Neck Surg, 138(11), pp.1030~1033 (2012)
  459. Eskander A, "Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: a systematic review and meta-analysis", Thyroid, 23(5), pp.583~592 (2013)
  460. Schuff KG, "Management of recurrent", persistent papillary thyroid carcinoma: efficacy of the surgical option, 2011, pp.96(7), 2038~2039
  461. McCoy KL, "Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer", Surgery, 142(6), pp.965~972 (2007)
  462. Hughes DT, "Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin", Ann Surg Oncol, 19(9), pp.2951~2957 (2012)
  463. Roh JL, "Central compartment reoperation for recurrent", persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia, 2011, pp.18(5), 1312~1318
  464. Shaha AR, "Recurrent differentiated thyroid cancer", Endocr Pract, 18(4), pp.600~603 (2012)
  465. Palme CE, "Management and outcome of recurrent welldifferentiated thyroid carcinoma", Arch Otolaryngol Head Neck Surg, 130(7), pp.819~824 (2004)
  466. Clayman GL, "Long-term outcome of comprehensive central compartment dissection in patients with recurrent", persistent papillary thyroid carcinoma, 2011, pp.21(12), 1309~1316
  467. Clayman GL, "Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma", Head Neck, 31(9), pp.1152~1163 (2009)
  468. Chao TC, "Reoperative thyroid surgery", World J Surg, 21(6), pp.644~647 (1997)
  469. Erbil Y, "Radio-guided excision of metastatic lymph nodes in thyroid carcinoma: a safe technique for previously operated neck compartments", World J Surg, 34(11), pp.2581~2588 (2010)
  470. Alzahrani AS, "Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent", persistent papillary thyroid cancer, 2002, pp.25(6), 526~531
  471. Travagli JP, "Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma", J Clin Endocrinol Metab, 83(8), pp.2675~2680 (1998)
  472. Lee L, "Sonographically-directed neck dissection for recurrent thyroid carcinoma", Laryngoscope, 118(6), pp.991~994 (2008)
  473. Steward DL, "Update in utility of secondary node dissection for papillary thyroid cancer", J Clin Endocrinol Metab, 97(10), pp.3393~3398 (2012)
  474. Rubello D, "99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer", Eur J Surg Oncol, 33(7), pp.902~906 (2007)
  475. Shin JE, "Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges", Curr Opin Oncol, 25(1), pp.14~19 (2013)
  476. Baek JH, "Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation", AJR Am J Roentgenol, 197(2), pp.W331~W336 (2011)
  477. Perros P, "Guidelines for the management of thyroid cancer", Clin Endocrinol (Oxf), 81(Suppl 1), pp.1~122 (2014)
  478. Kim JH, "Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm", Radiology, 276(3), pp.909~918 (2015)
  479. Suh CH, "Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and meta-analysis", Thyroid, 26(3), pp.420~428 (2016)
  480. Owen RP, "Techniques for radiofrequency ablation of head and neck tumors", Arch Otolaryngol Head Neck Surg, 130(1), pp.52~56 (2004)
  481. Ge JH, "Surgical treatment of advanced thyroid carcinoma with aero-digestive invasion", Zhonghua Er Bi Yan Hou Ke Za Zhi, 39(4), pp.237~240 (2004)
  482. Avenia N, "Locally advanced thyroid cancer: therapeutic options", Chir Ital, 56(4), pp.501~508 (2004)
  483. McCaffrey JC, "Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma", Cancer Control, 7(3), pp.246~252 (2000)
  484. Musholt TJ, "Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon", Surgery, 126(6), pp.1078~1087 (1999)
  485. Czaja JM, "The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma", Arch Otolaryngol Head Neck Surg, 123(5), pp.484~490 (1997)
  486. Shindo ML, "Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement", Head Neck, 36(10), pp.1379~1390 (2014)
  487. Haymart MR, "Disease severity and radioactive iodine use for thyroid cancer", J Clin Endocrinol Metab, 98(2), pp.678~686 (2013)
  488. Van Nostrand D, "The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer", Thyroid, 19(12), pp.1381~1391 (2009)
  489. Van Nostrand D, "Radioiodine in the treatment of thyroid cancer", Endocrinol Metab Clin North Am, 36(3), pp.807~822 (2007)
  490. Van Nostrand D, "Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma", Thyroid, 12(2), pp.121~134 (2002)
  491. Chiesa C, "Individualized dosimetry in the management of metastatic differentiated thyroid cancer", Q J Nucl Med Mol Imaging, 53(5), pp.546~561 (2009)
  492. Thomas SR, "In vivo quantitation of lesion radioactivity using external counting methods", Med Phys, 03(04), pp.253~255 (1976)
  493. Holst JP, "Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis", Thyroid, 15(12), pp.1321~1331 (2005)
  494. Driedger AA, "A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure", Clin Nucl Med, 31(8), pp.454~457 (2006)
  495. Jarzab B, "Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review", Endocr Relat Cancer, 12(4), pp.773~803 (2005)
  496. Verburg FA, "I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer", J Clin Endocrinol Metab, 96(8), pp.E1268~E1271 (2011)
  497. Ma C, "Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer", Cochrane Database Syst Rev, 11, pp.CD008302~ (2010)
  498. Sgouros G, "Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software", J Nucl Med, 45(8), pp.1366~1372 (2004)
  499. Jentzen W, "Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer", J Nucl Med, 49(6), pp.1017~1023 (2008)
  500. Pettinato C, "Usefulness of 124I PET", CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I, 2012, pp.56(6), 509~514
  501. Schlumberger M, "Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients", Nat Clin Pract Endocrinol Metab, 3(3), pp.260~269 (2007)
  502. Kulkarni K, "The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer", Thyroid, 16(10), pp.1019~1023 (2006)
  503. Tuttle RM, "Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer", J Nucl Med, 47(10), pp.1587~1591 (2006)
  504. Klubo-Gwiezdzinska J, "Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin", Thyroid, 22(3), pp.310~317 (2012)
  505. Rudavsky AZ, "Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone", J Clin Endocrinol Metab, 82(1), pp.11~14 (1997)
  506. Ringel MD, "Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism", J Clin Endocrinol Metab, 81(5), pp.1724~1725 (1996)
  507. Luster M, "Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma", J Clin Endocrinol Metab, 85(10), pp.3640~3645 (2000)
  508. Mariani G, "Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer", Cancer Biother Radiopharm, 15(2), pp.211~217 (2000)
  509. Perros P, "Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience", J Endocrinol Invest, 22(11 Suppl), pp.30~34 (1999)
  510. Lippi F, "Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH", Eur J Endocrinol, 144(1), pp.5~11 (2001)
  511. Pellegriti G, "Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer", Thyroid, 11(11), pp.1025~1030 (2001)
  512. Adler ML, "Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin", Endocr Pract, 4(5), pp.282~286 (1998)
  513. Chiu AC, "Prognosis and treatment of brain metastases in thyroid carcinoma", J Clin Endocrinol Metab, 82(11), pp.3637~3642 (1997)
  514. Lau WF, "Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy", Intern Med J, 36(9), pp.564~570 (2006)
  515. Potzi C, "Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients", Clin Endocrinol (Oxf), 65(4), pp.519~523 (2006)
  516. Pons F, "Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma", Clin Nucl Med, 12(8), pp.644~647 (1987)
  517. Koong SS, "Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma", J Clin Endocrinol Metab, 84(3), pp.912~916 (1999)
  518. Liu YY, "Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies", Clin Endocrinol (Oxf), 64(6), pp.617~624 (2006)
  519. Lin JD, "Papillary thyroid carcinomas with lung metastases", Thyroid, 14(12), pp.1091~1096 (2004)
  520. Shoup M, "Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma", J Am Coll Surg, 197(2), pp.191~197 (2003)
  521. Pittas AG, "Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients", Thyroid, 10(3), pp.261~268 (2000)
  522. Dinneen SF, "Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades", J Clin Endocrinol Metab, 80(7), pp.2041~2045 (1995)
  523. Foote RL, "Is there a role for radiation therapy in the management of Hurthle cell carcinoma", Int J Radiat Oncol Biol Phys, 56(4), pp.1067~1072 (2003)
  524. Pak H, "Role of metastasectomy in the management of thyroid carcinoma: the NIH experience", J Surg Oncol, 82(1), pp.10~18 (2003)
  525. Vitale G, "Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer", Br J Cancer, 84(12), pp.1586~1590 (2001)
  526. Kitamura Y, "Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases", J Clin Endocrinol Metab, 84(11), pp.4043~4049 (1999)
  527. Brose MS, "Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma", Expert Rev Anticancer Ther, 12(9), pp.1137~1147 (2012)
  528. Sabra MM, "Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases", J Clin Endocrinol Metab, 98(5), pp.E829~E836 (2013)
  529. Ho AL, "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer", N Engl J Med, 368(7), pp.623~632 (2013)
  530. Benua RS, "The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer", Am J Roentgenol Radium Ther Nucl Med, 87, pp.171~182 (1962)
  531. Hod N, "Differentiated thyroid carcinoma in children and young adults: evaluation of response to treatment", Clin Nucl Med, 30(6), pp.387~390 (2005)
  532. Fatourechi V, "Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer", J Clin Endocrinol Metab, 87(4), pp.1521~1526 (2002)
  533. Koh JM, "Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study", Clin Endocrinol (Oxf), 58(4), pp.421~427 (2003)
  534. Ma C, "Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases", Cochrane Database Syst Rev, (1), pp.CD006988~ (2009)
  535. Sabra MM, "Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans", Thyroid, 22(9), pp.877~883 (2012)
  536. -fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine, "Thyroid", 2001, 1169~1175
  537. Salvatore B, "Fluorodeoxyglucose PET", CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation, 2008, pp.52(1), 2~8
  538. Kloos RT, "Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer", J Clin Endocrinol Metab, 93(5), pp.1519~1525 (2008)
  539. van Tol KM, "Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin", Eur J Endocrinol, 148(6), pp.589~596 (2003)
  540. Kabasakal L, "Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases", Eur J Nucl Med Mol Imaging, 31(11), pp.1500~1504 (2004)
  541. Yim JH, "Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer", Thyroid, 23(1), pp.58~63 (2013)
  542. Black EG, "Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 27(1), pp.115~120 (1987)
  543. Huang SH, "Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis", Thyroid, 16(12), pp.1273~1278 (2006)
  544. Schlumberger M, "131I therapy for elevated thyroglobulin levels", Thyroid, 7(2), pp.273~276 (1997)
  545. Ma C, "Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results", J Nucl Med, 46(7), pp.1164~1170 (2005)
  546. Chao M, "Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan", Clin Oncol (R Coll Radiol), 22(6), pp.438~447 (2010)
  547. Sinha P, "Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome", Anticancer Res, 31(6), pp.2109~2112 (2011)
  548. Ozata M, "Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer", J Clin Endocrinol Metab, 79(1), pp.98~105 (1994)
  549. Kim WG, "Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18Ffluorodeoxyglucose positron emission tomography scan", J Clin Endocrinol Metab, 95(3), pp.1169~1173 (2010)
  550. Biko J, "Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up", Eur J Nucl Med Mol Imaging, 38(4), pp.651~655 (2011)
  551. Walter MA, "The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study", J Nucl Med, 48(10), pp.1620~1625 (2007)
  552. Kloos RT, "Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma", J Clin Endocrinol Metab, 87(12), pp.5817~5820 (2002)
  553. Brown AP, "The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer", J Clin Endocrinol Metab, 93(2), pp.504~515 (2008)
  554. Rubino C, "Second primary malignancies in thyroid cancer patients", Br J Cancer, 89(9), pp.1638~1644 (2003)
  555. Sandeep TC, "Second primary cancers in thyroid cancer patients: a multinational record linkage study", J Clin Endocrinol Metab, 91(5), pp.1819~1825 (2006)
  556. Subramanian S, "Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis", Thyroid, 17(12), pp.1277~1288 (2007)
  557. Nakada K, "Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer", J Nucl Med, 46(2), pp.261~266 (2005)
  558. Jentzen W, "The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(", CT) imaging, 2010, pp.37(12), 2298~2306
  559. Van Nostrand D, "Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice", Thyroid, 20(10), pp.1113~1119 (2010)
  560. Mandel SJ, "Radioactive iodine and the salivary glands", Thyroid, 13(3), pp.265~271 (2003)
  561. Bomeli SR, "Interventional sialendoscopy for treatment of radioiodineinduced sialadenitis", Laryngoscope, 119(5), pp.864~867 (2009)
  562. Prendes BL, "Therapeutic sialendoscopy for the management of radioiodine sialadenitis", Arch Otolaryngol Head Neck Surg, 138(1), pp.15~19 (2012)
  563. Bhayani MK, "Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia", Thyroid, 25(7), pp.834~838 (2015)
  564. Sawka AM, "Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis", Thyroid, 19(5), pp.451~457 (2009)
  565. Iyer NG, "Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy", Cancer, 117(19), pp.4439~4446 (2011)
  566. Chen AY, "The development of breast carcinoma in women with thyroid carcinoma", Cancer, 92(2), pp.225~231 (2001)
  567. Berthe E, "Risk of second primary cancer following differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 31(5), pp.685~691 (2004)
  568. Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 35(10), pp.1941~1959 (2008)
  569. Perry WF, "The urinary excretion and thyroid uptake of iodine in renal disease", J Clin Invest, 31(5), pp.457~463 (1952)
  570. Vini L, "Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer", Postgrad Med J, 78(916), pp.92~93 (2002)
  571. Dottorini ME, "Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma", J Nucl Med, 36(1), pp.21~27 (1995)
  572. Sawka AM, "A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors", Clin Endocrinol (Oxf), 69(3), pp.479~490 (2008)
  573. Wu JX, "Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer", Thyroid, 25(1), pp.133~138 (2015)
  574. American Thyroid Association Taskforce On Radioiodine Safety, "Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association", Thyroid, 21(4), pp.335~346 (2011)
  575. Bernard N, "Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey", BJOG, 122(9), pp.1244~1251 (2015)
  576. Wichers M, "Testicular function after radioiodine therapy for thyroid carcinoma", Eur J Nucl Med, 27(5), pp.503~507 (2000)
  577. Hyer S, "Testicular dose and fertility in men following I(131) therapy for thyroid cancer", Clin Endocrinol (Oxf), 56(6), pp.755~758
  578. Lushbaugh CC, "The effects of gonadal irradiation in clinical radiation therapy: a review", Cancer, 37(2Suppl), pp.1111~1125 (1976)
  579. Sarkar SD, "Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer", J Nucl Med, 17(6), pp.460~464 (1976)
  580. Mazzaferri EL, "Gonadal damage from 131I therapy for thyroid cancer", Clin Endocrinol (Oxf), 57(3), pp.313~314 (2002)
  581. Schlumberger M, "Definition and management of radioactive iodine-refractory differentiated thyroid cancer", Lancet Diabetes Endocrinol, 2(5), pp.356~358 (2014)
  582. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
  583. Lo SS, "Stereotactic body radiation therapy: a novel treatment modality", Nat Rev Clin Oncol, 7(1), pp.44~54 (2010)
  584. Lo SS, "Stereotactic body radiation therapy for oligometastases", Expert Rev Anticancer Ther, 9(5), pp.621~635 (2009)
  585. Goetz MP, "Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study", J Clin Oncol, 22(2), pp.300~306 (2004)
  586. Dupuy DE, "Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial", Cancer, 116(4), pp.989~997 (2010)
  587. Van Tol KM, "Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma", Clin Endocrinol (Oxf), 52(5), pp.653~659 (2000)
  588. Coleman R, "Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II", III breast cancer, 2011, pp.127(2), 429~438
  589. Wardley A, "Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration", Br J Cancer, 92(10), pp.1869~1876 (2005)
  590. Orita Y, "Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma", Thyroid, 21(1), pp.31~35 (2011)
  591. McWilliams RR, "Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years", Cancer, 98(2), pp.356~362 (2003)
  592. Anderson RT, "Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review", Thyroid, 23(4), pp.392~407 (2013)
  593. Leboulleux S, "Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial", Lancet Oncol, 13(9), pp.897~905 (2012)
  594. Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
  595. Schlumberger M, "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer", N Engl J Med, 372(7), pp.621~630 (2015)
  596. Droz JP, "Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy", Tumori, 76(5), pp.480~483 (1990)
  597. Schutz FA, "Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors", J Clin Oncol, 30(8), pp.871~877 (2012)
  598. Cohen EE, "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study", J Clin Oncol, 26(29), pp.4708~4713 (2008)
  599. Bible KC, "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study", Lancet Oncol, 11(10), pp.962~972 (2010)
  600. Carr LL, "Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation", Clin Cancer Res, 16(21), pp.5260~5268 (2010)
  601. Schlumberger M, "A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)", J Clin Oncol, 32(5suppl), pp.LBA6008~ (2014)
  602. Massicotte MH, "Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network", Eur J Endocrinol, 170(4), pp.575~582 (2014)

관련 논문AI추천

분화갑상선암의 수술적 치료 권고안권형주, 김이수, 김훈엽, 남기현, 박경식, 박민호, 박진우, 배자성, 윤정한, 윤지섭, 윤현조, 이규언, 이수정, 임치영, 정기욱, 정진향, 최준호, 대한갑상선내분비외과학회 진료권고안위원회대한내분비외과학회 · Journal of Endocrine Surgery2017 · 제17권 제1호2025 대한갑상선학회 저위험 갑상선유두암 적극적 관찰 진료권고안강승헌, 구본석, 김경식, 김미진, 김민주, 김보현, 김선욱, 김지수, 김지훈, 나동규, 문신제, 박영주, 백교림, 송영신, 안종혁, 안화영, 원호륜, 유원상, 이민경, 이은경, 이정민, 이지예, 임동준, 정경연, 정찬권, 조윤영대한갑상선학회 · International Journal of Thyroidology2025 · 제18권 제1호갑상선기능항진증의 진단 및 치료- 대한갑상선학회 합의안김인주, 문재훈, 범희승, 송영기, 이가희, 이재태, 정웅윤, 정재훈대한갑상선학회 · International Journal of Thyroidology2013 · 제6권 제1호2025 갑상선기능항진증의 방사성요오드 치료에 대한 진료권고안강호철, 구유정, 권현우, 권혜미, 김경진, 김미진, 김선욱, 김신곤, 김지수, 김태용, 나동규, 박영주, 송의연, 윤지희, 이원우, 이은경, 임동준, 정재훈대한갑상선학회 · International Journal of Thyroidology2025 · 제18권 제1호대한갑상선학회 갑상선결절 진료권고안 2024강수환, 강호철, 구본석, 김선욱, 김원배, 나동규, 박도준, 박영주, 백승국, 송영신, 오소원, 이가희, 이민경, 이상우, 이영아, 이용상, 이은경, 이지예, 임동준, 정유석, 정윤재, 정찬권, 조윤영, 주리히대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제1호대한갑상선학회 갑상선분화암 진료권고안 2024 어떻게 바뀌었나: 진단부터 초기치료까지이은경대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제2호

이 간행물의 다른 논문 (15건)

갑상선자극호르몬이 골대사에 미치는 영향조선욱pp. 127-130구강 접근을 통한 갑상설관 낭종 수술우승훈pp. 131-136Thyroid Volume Measured by 99mTc-Pertechnetate Scintigraphy and Its Relationship with Clinical Parameters in Korean Patients with Autoimmune Thyroiditis이상아, Seong Man Lee, Young Hwan Kim, So-Yeon Yoo, Gwanpyo Kohpp. 137-144Subacute Thyroiditis and Painless Thyroiditis: Clinical Characteristics of 221 Patients Diagnosed between 2009 and 2015In Hye Lee, Ji Su Kim, Go Eul Kim, Won Il Park, Dong Hyun Shin, Jung Ah Choi, Yong Hyun Kim, Jae Min Lee, Jin Young Heo, Hyun Mi Kim, Chul Young Kimpp. 145-151Selenium Concentration in Korean Patients with Thyroid Disease: a Preliminary Report장주영, 김태혁, 조윤영, 김선욱, 정재훈pp. 152-158
원문 보기